Navigation Links
Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
Date:8/4/2010

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the appointment of Antonin (Tony) de Fougerolles, Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment as Tolerx’s CSO will provide leadership for the company’s research and early-stage product development programs involving novel therapies based on T cell modulation.  Dr. de Fougerolles brings to Tolerx more than 15 years of biotech R&D experience and expertise in immunology. He will direct the company’s R&D activities and strengthen Tolerx’s leadership in T cell immunology.

(Photo: http://photos.prnewswire.com/prnh/20100804/NE45601 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100804/NE45601 )

"We are delighted and enthusiastic about Tony joining us as CSO at this pivotal time, when Tolerx is poised to make substantial progress in expanding our pipeline of drug candidates based on T cell modulation," said Dr. Douglas J. Ringler, Chief Executive Officer of Tolerx. "Tony brings world-class R&D experience from well-known biotech companies, and his skills and expertise will extend our scientific leadership in T cell modulation and help lead Tolerx through our next stage of growth as we broaden our pipeline of innovative T cell therapies.”

Prior to joining Tolerx, Dr. de Fougerolles was Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals.  Dr. de Fougerolles joined Alnylam in 2003, holding positions of increasing responsibility and playing a key role in the development of several research programs, including those with Alnylam partners Novartis and Roche. Before joining Alnylam, he served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.), where he had worked since 1998. At Biogen, Dr. de Fougerolles worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. Dr. de Fougerolles earned his Ph.D. in Immunology from Harvard University, and was a Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

“I am very excited to join Tolerx at this time of transformational growth, and believe the depth and quality of Tolerx’s team and expertise in T cell modulation position the company to significantly advance and build its pipeline of new therapeutics,” said Dr. de Fougerolles. “I am particularly enthusiastic about helping to advance the product pipeline and playing a key role in developing novel therapies that are on the cutting edge of exploiting the science of T cell activity to treat autoimmune diseases and cancer in fundamentally new ways."

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity.  The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.  TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward humoral immune responses.  The company also has three pre-clinical candidates, TRX518, TRX585, and TRX385, that enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.  For more information, please visit www.tolerrx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
2. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
3. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
4. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
7. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
8. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
9. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
10. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
11. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Pipeline Database" newsletter to their offering. ... , , ... La Merie Publishing,s proprietary R&D Drug Pipeline Database provides 24/7 online ... therapeutic drugs on the market and on investigational drug candidates in ...
(Date:12/2/2016)... the largest share in the ECG Cables And ECG Leadwires ... remote monitoring ECG devices. On the other hand, the ... the highest growth rate during the forecast period. ... Company (U.S.), Medtronic plc ( Ireland ), Koninklijke ... Medical International Limited ( China ), held major ...
(Date:12/2/2016)... Quantum Radiology,s Mobile Breast Center (QR MBC) brings cutting-edge ... at the workplace, thereby maximizing convenience and compliance.  QR ... and SunTrust Bank, and community health groups to provide ... "I think it,s a great service for ... a mammogram without taking a large amount of time ...
Breaking Medicine Technology:
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local frontline ... field of pain management. , The demand for supplemental training related to ...
(Date:12/2/2016)... Texas (PRWEB) , ... December 02, 2016 , ... Yisrayl ... that delves into how this current generation fits into Bible Prophecy. Yisrayl says this ... various facts pointing to this conclusion, showing how the details line up exactly with ...
Breaking Medicine News(10 mins):